Phase 3 Dermatitis, Atopic trials in Poland: Trial Insights

Filters: Condition: Dermatitis, Atopic Phase: Phase 3 Country / region: Poland Clear all

58 trials match Source: ClinicalTrials.gov registrations

Trials started per year
Category	Trials
2004	1
2011	1
2013	2
2014	2
2015	1
2016	1
2017	4
2018	14
2019	6
2020	5
2021	1
2022	5
2023	7
2024	5
2025	2

Trials by status
Category	Trials
Completed	47
Active, not recruiting	6
Recruiting	2
Terminated	2
Enrolling by invitation	1

Top lead sponsors
Category	Trials
Eli Lilly and Company	11
Pfizer	8
LEO Pharma	7
Regeneron Pharmaceuticals	6
Amgen	5
Incyte Corporation	5
AbbVie	4
Sanofi	3
Almirall, S.A.	2
Astellas Pharma Inc	2

Top conditions
Category	Trials
Dermatitis, Atopic	58
Eczema	30
Dermatitis	9
Pruritus	6
Skin Diseases	6
Genetic Diseases, Inborn	2
Hypersensitivity	2
Hypersensitivity, Immediate	2
Immune System Diseases	2
Skin Diseases, Eczematous	2

Trials

Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.

A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema NCT06807281Phase 3RecruitingPfizerStarted 2025
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis NCT06832618Phase 3Active, not recruitingIncyte CorporationStarted 2025
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Phase 3Active, not recruitingAbbVieStarted 2024
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis NCT06311682Phase 3RecruitingLEO PharmaStarted 2024
A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06407934Phase 3Active, not recruitingSanofiStarted 2024
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis NCT06238817Phase 3CompletedIncyte CorporationStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor NCT06241118Phase 3Active, not recruitingSanofiStarted 2024
A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis NCT06130566Phase 3CompletedSanofiStarted 2023
A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic Therapy NCT05958407Phase 3CompletedLEO PharmaStarted 2023
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05882877Phase 3TerminatedAmgenStarted 2023
Long-term Safety and Efficacy of Lebrikizumab in Adult and Adolescent Participant With Moderate-to-Severe Atopic Dermatitis NCT05916365Phase 3CompletedAlmirall, S.A.Started 2023
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05704738Phase 3CompletedAmgenStarted 2023
A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis NCT05735483Phase 3Enrolling by invitationEli Lilly and CompanyStarted 2023
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD) NCT05724199Phase 3CompletedAmgenStarted 2023
A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) NCT05651711Phase 3CompletedAmgenStarted 2022
A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis NCT05601882Phase 3CompletedAbbVieStarted 2022
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis NCT05559359Phase 3Active, not recruitingEli Lilly and CompanyStarted 2022
Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis NCT05456529Phase 3CompletedIncyte CorporationStarted 2022
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) NCT05398445Phase 3CompletedAmgenStarted 2022
A Study of Lebrikizumab in Combination With Topical Corticosteroids in Patients With Atopic Dermatitis (AD) That Are Not Adequately Controlled With or Are Non-eligible for Cyclosporine NCT05149313Phase 3CompletedAlmirall, S.A.Started 2021
Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin) NCT04392154Phase 3CompletedEli Lilly and CompanyStarted 2020
Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy NCT04345367Phase 3CompletedPfizerStarted 2020
Study to Assess the Safety and Efficacy of Lebrikizumab (LY3650150) in Adolescent Participants With Moderate-to-Severe Atopic Dermatitis NCT04250350Phase 3CompletedEli Lilly and CompanyStarted 2020
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. NCT04250337Phase 3CompletedEli Lilly and CompanyStarted 2020
Open-Label Extension Study of Upadacitinib in Adult Participants With Moderate to Severe Atopic Dermatitis NCT04195698Phase 3CompletedAbbVieStarted 2020

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Status changeRecruiting to Active, not recruitingOctober 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Enrollment change675 to 699October 18, 2026
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis NCT06461897Completion date change2030-07-31 to 2029-11-30October 18, 2026

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.

Visit Pharma Observatory